# Global Point of Care (POC) Immunoassay Analyzer Expansion Market 2026 | Capture 8.8% CAGR to 2030 as Roche, Abbott, Siemens Healthineers and Danaher Scale AI-Enabled POC Testing

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/global-point-of-care-poc-immunoassay-analyzer-expansion-market-2026-capture-8-8-cagr-to-20/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Boost ROI via portable multiplex analyzers, AI and wireless connectivity, at-home testing, recurring service revenue, and acquisitions that expand decentralized diagnostics.*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6254939/point-care-poc-ma-immunoassay-analyzer?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=597ndk&amp;utm_campaign=2404367+-+Global+Point+of+Care+(POC)+Immunoassay+Analyzer+Expansion+Market+2026+%7c+Capture+8.8%25+CAGR+to+2030+as+Roche%2c+Abbott%2c+Siemens+Healthineers+and+Danaher+Scale+AI-Enabled+POC+Testing&amp;utm_exec=clshmsai" rel="nofollow">"Point of Care (POC) Immunoassay Analyzer Expansion Market Report 2026"</a> has been added to **ResearchAndMarkets.com's** offering.

The global point-of-care (POC) immunoassay analyzer expansion market is experiencing strong growth as healthcare providers increase their use of rapid, decentralized diagnostic technologies. The market is projected to grow from $4.9 billion in 2025 to $5.31 billion in 2026, representing a compound annual growth rate (CAGR) of 8.6%. Historical growth has been supported by the rising prevalence of infectious diseases, expanding hospital laboratory infrastructure, increasing demand for rapid diagnostics, wider adoption of immunoassay technology, and improvements in antigen and antibody detection methods.

Looking ahead, the point-of-care immunoassay analyzer market is forecast to reach $7.45 billion by 2030, growing at a CAGR of 8.8%. Key growth drivers include the expansion of personalized medicine and biomarker-based testing, the shift toward decentralized healthcare delivery, greater adoption of artificial intelligence-enabled diagnostic systems, growth in home-based health monitoring, and increasing regulatory approvals for rapid diagnostic devices.

Several market trends are expected to shape the industry through 2030. These include the development of decentralized point-of-care diagnostic ecosystems, rising adoption of multiplex immunoassay platforms, integration of wireless connectivity into portable analyzers, expansion of cartridge-based rapid testing systems, and growing demand for at-home immunodiagnostic solutions. Together, these trends are improving diagnostic accessibility, shortening turnaround times, and supporting faster clinical decision-making across hospitals, clinics, emergency departments, and remote care settings.

The increasing prevalence of infectious diseases remains a major factor driving demand for point-of-care immunoassay analyzers. Rising global population density and increased transmission risks are contributing to the need for rapid, accurate, and accessible diagnostic testing. POC immunoassay systems support early detection by identifying infectious biomarkers near the patient, helping healthcare professionals initiate treatment sooner and strengthen disease surveillance and control.

Recent public health data highlights this growing need. In March 2025, the UK Health Security Agency reported that tuberculosis cases in England rose by 13% during 2024, reaching 5,480 cases compared with 4,850 cases in 2023. Such increases reinforce the importance of scalable diagnostic solutions capable of delivering timely results outside centralized laboratory environments.

Innovation in immunoassay technology is also accelerating market expansion. Manufacturers are focusing on compact automated platforms that offer high sensitivity, minimal sample preparation, rapid turnaround times, portability, and multiplex testing capabilities. These developments are particularly relevant for decentralized healthcare, emergency diagnostics, outpatient clinics, and locations with limited laboratory infrastructure.

In July 2023, Anbio Biotechnology launched the AF-100S Fluorescence Immunoassay Analyzer. The compact automated system supports rapid quantitative detection of biomarkers in whole blood, serum, and plasma. It combines fluorescence-based detection with automated calibration and integrated quality control to support reliable clinical testing. The analyzer also features a user-friendly interface and can provide results within minutes, making it suitable for emergency departments, clinics, and decentralized healthcare environments.

Strategic acquisitions are further strengthening the competitive landscape. In August 2024, Roche acquired LumiraDx's point-of-care technology assets for an undisclosed amount. The acquisition is intended to expand Roche's diagnostics portfolio by integrating LumiraDx's point-of-care testing platform and immunoassay-based capabilities. It also supports Roche's broader presence in decentralized healthcare and rapid diagnostic testing.

North America was the largest region in the point-of-care immunoassay analyzer expansion market in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.

**Markets Covered:**  
1) By Product Type: Portable Analyzers; Benchtop Analyzers; Microfluidic Analyzers  
2) By Technology: Chemiluminescence; Enzyme-Linked Immunosorbent Assay; Lateral Flow Assay  
3) By Sample Type: Blood; Urine; Saliva  
4) By Application: Infectious Diseases; Hormonal Testing; Autoimmune Disorders; Cardiac Markers; Oncology  
5) By End User: Hospitals; Diagnostic Laboratories; Home Care Settings; Academic Research Institutions

**Subsegments:**  
1) By Portable Analyzers: Handheld Immunoassay Analyzers; Battery Operated Diagnostic Analyzers; Wireless Connected Portable Analyzers; Single Test Portable Analyzers; Multi Test Portable Analyzers  
2) By Benchtop Analyzers: Compact Laboratory Benchtop Analyzers; High Throughput Benchtop Analyzers; Fully Automated Benchtop Analyzers; Semi Automated Benchtop Analyzers; Multi Assay Benchtop Systems  
3) By Microfluidic Analyzers: Lab On A Chip Analyzers; Cartridge Based Microfluidic Analyzers; Continuous Flow Microfluidic Systems; Droplet Based Microfluidic Analyzers; Integrated Microfluidic Diagnostic Systems

**Time Series:** Five years historic and ten years forecast.

**Data:** Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

**Data Segmentation:** Country and regional historic and forecast data, market share of competitors, market segments.

**Key Attributes:**  
  

| Report Attribute | Details |
| --- | --- |
| No. of Pages | 250 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value (USD) in 2026 | $5.31 Billion |
| Forecasted Market Value (USD) by 2030 | $7.45 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |

  
**Companies Featured**  
  
The companies featured in this Point of Care (POC) Immunoassay Analyzer Expansion market report include:

-   F. Hoffmann-La Roche Ltd.
-   Thermo Fisher Scientific
-   Abbott Laboratories
-   Siemens Healthineers AG
-   Danaher Corporation
-   Becton
-   Dickinson and Company (BD)
-   Beckman Coulter
-   Bruker Corporation
-   BioRad Laboratories
-   Qiagen N.V.
-   Diasorin
-   Lepu Medical Technology
-   SD Biosensor
-   Eiken Chemical Co. Ltd.
-   Molbio Diagnostics Pvt. Ltd.
-   Maccura Biotechnology Co. Ltd.
-   QuantuMDx Group Ltd.
-   Ustar Biotechnologies Ltd.
-   Mylab Discovery Solutions Pvt Ltd.
-   Akonni Biosystems Inc.
-   Zeesan Biotech Co. Ltd.

For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6254939/point-care-poc-ma-immunoassay-analyzer?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=597ndk&amp;utm_campaign=2404367+-+Global+Point+of+Care+(POC)+Immunoassay+Analyzer+Expansion+Market+2026+%7c+Capture+8.8%25+CAGR+to+2030+as+Roche%2c+Abbott%2c+Siemens+Healthineers+and+Danaher+Scale+AI-Enabled+POC+Testing&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/2h2xlf</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/YTc5NDI2ZjItNjU0OC00ODM1LWE0ZDItZjk5YmMyNzRhOTg2LTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [In Vivo Imaging Systems Market - Global Forecast 2026-2032 | AI and Multimodal Platforms Drive 12.68% CAGR, Creating a USD 3.86 Billion Opportunity by 2032](https://healthcarenews.io/news/in-vivo-imaging-systems-market-global-forecast-2026-2032-ai-and-multimodal-platforms-drive.md)
- [EAACI calls for allergy and respiratory health to be part of climate action at COP31](https://healthcarenews.io/news/eaaci-calls-for-allergy-and-respiratory-health-to-be-part-of-climate-action-at-cop31.md)
- [Global Preclinical Contract Research Organization (CRO) Market - Forecast 2026-2032 | AI and Advanced Therapies Drive 8.93% CAGR, Creating a USD 12.76 Billion Market by 2032](https://healthcarenews.io/news/global-preclinical-contract-research-organization-cro-market-forecast-2026-2032-ai-and-adv.md)
- [EAACI connects allergy research with public action on anaphylaxis in Utrecht](https://healthcarenews.io/news/eaaci-connects-allergy-research-with-public-action-on-anaphylaxis-in-utrecht.md)
